Company Filing History:
Years Active: 2019-2025
Title: Yutaka Nishimoto: Innovator in Cryopreservation and Pharmaceutical Stability
Introduction
Yutaka Nishimoto is a prominent inventor based in Osaka, Japan. He has made significant contributions to the fields of cryopreservation and pharmaceutical formulations. With a total of 2 patents, his work focuses on improving the stability and efficacy of various compounds.
Latest Patents
Nishimoto's latest patents include innovative compositions and methods for cryopreserving cells. One of his notable inventions is a cryopreservation medium designed for mammalian cells. This medium comprises dimethyl sulfoxide (DMSO), disaccharide, human serum, and IL-7 and/or IL-15. The formulation allows for effective cryopreservation, ensuring cell viability during storage. Another patent involves a solid preparation that enhances the stability of a specific compound, N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea. This preparation includes a method for stabilizing the compound in a solid form, utilizing a fat and oil-like substance with a low melting point.
Career Highlights
Yutaka Nishimoto is currently employed at Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His work at Takeda has allowed him to focus on innovative solutions that address critical challenges in the pharmaceutical industry. His expertise in cryopreservation and solid preparation formulations has positioned him as a valuable asset in his field.
Collaborations
Nishimoto collaborates with esteemed colleagues, including Ikuro Yamane and Yukihiro Nomura. These partnerships enhance the research and development efforts within Takeda, fostering an environment of innovation and excellence.
Conclusion
Yutaka Nishimoto's contributions to cryopreservation and pharmaceutical stability exemplify the impact of innovative thinking in the medical field. His patents reflect a commitment to advancing technology that benefits both researchers and patients.